Therefore, radiotherapy combined with IL-4 signaling inhibitors and/or second-generation M1-polarized CAR or in combination with medicine targeting cancer Tregs [38] might become a next-generation regimen for radioimmunotherapy. This evidence concerns the gene IL4 and cancer.